everis has developed a solution based on Artificial Intelligence and aimed at treating patients who have been diagnosed with bipolar disorder. Under the name Smart Remote Treatment (SRT), the consultancy's personalized medicine application seeks adherence in treatment, by encouraging the involvement of patients and healthcare professionals in the clinical method.
To explore and validate the mathematical models applied in the solution, the company has successfully carried out a multicenter study in Spain, demonstrating the validity of the calculation of the ideal lithium dose, one of the most widespread drugs in the treatment of bipolar disorder that helps to keep patients stable and reduce mood swings, as well as for the estimation of Litemia. This functionality acts as a clinical decision support system and could become an automatic prescribing tool in the future.
The study has also served to identify and address other opportunities of the solution that previously did not have, such as the incorporation of functionalities to monitor the mood of patients, besides their physical activity. The solution not only provides exact and personalized data of the patient treated but also serves as educational and explanatory support for the doctors with them. An example is a graphical interface so that clinicians can show patients how lifestyle affects their treatment.
Full validation and market launch
Although this personalized medicine tool is expected to be available to health services in mid-2021, it has already been presented at international conferences dedicated to psychiatry and neuropsychopharmacology, such as the National Congress of Psychiatry (CNP) or the European Clinical Neuropsychopharmacology Congress (ECNP).
On the other hand, looking for being able to provide the health services with a fully validated application, the latest validations will be carried out next February, mainly focused on usability from a clinical point of view and providing a greater capacity for taking advantage of the treatment of bipolar disorders.